International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 08 August 2024

Page No: 1533-1539

DOI: https://doi.org/10.47191/ijmscrs/v4-i08-20, Impact Factor: 7.949

Clinical and Molecular Insights into Buschke-Ollendorff Syndrome: A Comprehensive Review of Osteopoikilosis and Dermatofibrosis Lenticularis Disseminata

Martha Castro Carranza

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Clinica Hospital No.24 Ciudad Guzman

ABSTRACT

Buschke-Ollendorff Syndrome (BOS) is a rare genetic disorder characterized by the concurrent manifestation of osteopoikilosis and dermatofibrosis lenticularis disseminata. The syndrome is caused by mutations in the LEMD3 gene, leading to the dysregulation of TGF-β signaling pathways, which play a critical role in both bone and skin homeostasis. Clinically, BOS presents with asymptomatic, radiographically detectable osteopoikilosis—small, round, sclerotic bone lesions—and multiple yellow-brown papules distributed over the trunk and extremities, indicative of dermatofibrosis lenticularis disseminata. This review aims to provide a detailed exploration of the genetic and pathophysiological mechanisms underlying BOS, with an emphasis on the clinical manifestations, diagnostic approaches, and current management strategies. Additionally, this article discusses the implications of BOS for differential diagnosis in orthopedic and dermatologic practice, highlighting the importance of recognizing the syndromic association to avoid misdiagnosis. The potential for targeted therapies that address the underlying molecular defects in BOS will also be examined.

ARTICLE DETAILS

Published On:
27 August 2024

Available on:
https://ijmscr.org/

KEYWORDS: Buschke-Ollendorff Syndrome, osteopoikilosis, dermatofibrosis lenticularis disseminata, LEMD3 gene, TGF-β signaling, genetic disorder, sclerotic bone lesions, dermatologic manifestations, differential diagnosis

INTRODUCTION

Buschke-Ollendorff Syndrome (BOS), first described by Buschke in 1928 and later detailed by Ollendorff in 1929, is a rare autosomal dominant disorder that uniquely combines dermatological and osteological abnormalities. The syndrome is characterized by the presence of osteopoikilosis—multiple, discrete, benign bone lesions—and dermatofibrosis lenticularis disseminata, a skin condition marked by numerous small, firm, and yellow-brown papules. These manifestations are attributable to mutations in the LEMD3 gene, which encodes an inner nuclear membrane protein involved in the negative regulation of the TGF-β signaling pathway. Dysregulation of this pathway disrupts normal bone formation and skin architecture, leading to the phenotypic features observed in BOS.1

The clinical presentation of BOS is often subtle, with many patients remaining asymptomatic and the condition being incidentally discovered through radiographic examination for unrelated reasons. The sclerotic bone lesions of osteopoikilosis are typically non-progressive and do not lead to significant functional impairment. However, the cutaneous manifestations, while generally benign, can cause cosmetic concerns and may be mistaken for more serious dermatologic conditions. Given the rarity of the syndrome, it is frequently underdiagnosed or misdiagnosed, particularly in cases where only one of the hallmark features is present.1

This review seeks to consolidate current knowledge on BOS, focusing on the genetic basis, pathophysiology, and clinical features of the syndrome. We will explore the diagnostic criteria, including the role of imaging and histopathological examination, and discuss the differential diagnoses that should be considered. Furthermore, the article will review the current management strategies and potential future therapies that could offer more targeted treatment options for individuals with BOS.1

EPIDEMIOLOGY

Buschke-Ollendorff Syndrome (BOS) is a rare genetic disorder with an autosomal dominant inheritance pattern. The exact prevalence of BOS is not well established due to the rarity of the condition and the frequent underdiagnosis or misdiagnosis of its clinical manifestations. Estimates suggest that BOS may affect fewer than 1 in 100,000 individuals in the general population, although these figures are likely conservative, given the asymptomatic nature of the syndrome in many cases.1

The disorder shows no significant gender predilection, affecting males and females equally. The distribution of BOS appears to be global, with cases reported across various ethnicities and geographic regions, suggesting no particular population is at higher risk. However, the identification of BOS in clinical settings is often incidental, primarily during radiographic investigations for unrelated conditions, or through dermatological examination when the characteristic skin lesions prompt further evaluation.1

Familial clustering is a notable feature of BOS, consistent with its autosomal dominant mode of inheritance. Affected individuals typically have a family history of the syndrome, although sporadic cases can occur, potentially due to de novo mutations in the LEMD3 gene. The penetrance of the disorder is considered high, meaning that individuals carrying the pathogenic variant are likely to manifest some clinical features of the syndrome, although the severity and extent of these features can vary widely.1

The age of onset for the clinical manifestations of BOS is variable. Osteopoikilosis, the hallmark radiographic feature, can be present from birth but often remains undetected until later in life when incidental imaging reveals the characteristic sclerotic lesions. Dermatofibrosis lenticularis disseminata, the cutaneous component of BOS, may become apparent during childhood or adolescence, though it is not uncommon for the skin lesions to be overlooked or misinterpreted as other dermatological conditions, delaying the diagnosis.1

Due to the relatively benign nature of the bone and skin lesions associated with BOS, many individuals with the syndrome lead normal lives without significant morbidity. However, the rarity of the condition and its subtle clinical presentation contribute to the challenges in obtaining accurate epidemiological data. The lack of comprehensive registries or large-scale studies specifically focused on BOS further complicates the understanding of its true prevalence and demographic distribution.1

In clinical practice, BOS should be considered in patients presenting with unexplained sclerotic bone lesions on radiographs, particularly when accompanied by characteristic skin lesions. Given the potential for misdiagnosis, increasing awareness among healthcare providers, including radiologists, dermatologists, and geneticists, is essential for improving recognition and reporting of this rare syndrome. As molecular genetic testing becomes more accessible, it is likely that the identification of BOS will increase, potentially leading to a more accurate estimation of its epidemiology in the future.2

CLINICAL MANIFESTATIONS

Buschke-Ollendorff Syndrome (BOS) is characterized by a unique constellation of dermatological and osteological abnormalities, most notably dermatofibrosis lenticularis disseminata and osteopoikilosis. The clinical presentation of BOS can be highly variable, with some individuals displaying the full spectrum of manifestations, while others may present with only one of the hallmark features, complicating the diagnostic process.2

DERMATOLOGICAL MANIFESTATIONS

The dermatological hallmark of BOS is dermatofibrosis lenticularis disseminata, a condition characterized by the development of multiple, small, firm papules on the skin. These papules are typically 1-5 mm in diameter, with a yellow-brown or flesh-colored appearance. The lesions are usually asymptomatic, though they can be pruritic in some cases. They are most commonly distributed on the trunk and extremities but may also be found on the face, neck, and buttocks. Histologically, these lesions are characterized by an increased deposition of collagen in the dermis, often accompanied by a mild inflammatory infiltrate. The overlying epidermis may appear normal or slightly atrophic.2

The skin lesions associated with BOS are generally benign and do not pose a significant health risk; however, they can be a source of cosmetic concern for affected individuals. In some cases, the lesions may be mistaken for other dermatologic conditions, such as connective tissue nevi, elastomas, or papular mucinosis, leading to potential misdiagnosis. Given the rarity of BOS, dermatologists must maintain a high index of suspicion when encountering patients with unexplained, disseminated papules, particularly when these lesions are accompanied by radiographic findings consistent with osteopoikilosis.2

Osteological Manifestations

Osteopoikilosis, the primary osteological manifestation of BOS, is characterized by the presence of multiple, small, round or oval sclerotic lesions scattered throughout the trabecular bone. These lesions are typically 2-10 mm in size and are most commonly found in the epiphyses and metaphyses of long bones, as well as in the pelvis, carpal, and tarsal bones. Osteopoikilosis is usually discovered incidentally during radiographic examination for unrelated conditions, as the lesions are asymptomatic and do not cause any functional impairment or pain.2

Radiographically, the sclerotic lesions of osteopoikilosis appear as well-defined, homogeneously dense spots within the cancellous bone. They are usually symmetrical and are often described as "enostoses" or "bone islands." Unlike other

bone disorders, such as osteoblastic metastases or tuberous sclerosis, the lesions in osteopoikilosis do not increase in size or number over time and do not exhibit cortical involvement or periosteal reaction.2

Although osteopoikilosis is benign and does not lead to significant morbidity, its recognition is important to avoid unnecessary investigations or interventions. In rare cases, individuals with BOS may experience mild joint pain or stiffness, particularly in the large joints, though this is not typically a prominent feature of the syndrome. The presence of osteopoikilosis in combination with dermatofibrosis lenticularis disseminata should prompt consideration of BOS, especially in patients with a family history of the disorder.2

OTHER POTENTIAL MANIFESTATIONS

While dermatofibrosis lenticularis disseminata and osteopoikilosis are the primary clinical features of BOS, other manifestations may occasionally be present, reflecting the syndrome's systemic nature. These additional features are less common but can provide further clues to the diagnosis.2

- **Joint Abnormalities**: Some individuals with BOS may develop joint effusions, particularly in the knees, or experience arthralgia without overt arthritis. These symptoms are generally mild and do not lead to long-term joint damage.2
- **Bone Density Abnormalities**: Although osteopoikilosis itself does not affect overall bone density, there have been reports of individuals with BOS exhibiting reduced bone mineral density or osteopenia, particularly in postmenopausal women or older adults.
- **Cardiovascular Involvement**: Rarely, BOS may be associated with cardiovascular abnormalities, such as mitral valve prolapse or other structural heart defects. However, the connection between BOS and cardiovascular manifestations is not well established and requires further investigation.2
- **Connective Tissue Anomalies**: Given the involvement of the LEMD3 gene, which plays a role in the regulation of connective tissue, some patients with BOS may exhibit other connective tissue abnormalities, such as hypermobility, though these are not consistently observed.2

The clinical manifestations of Buschke-Ollendorff Syndrome are primarily dermatological and osteological, with dermatofibrosis lenticularis disseminata and osteopoikilosis serving as the key diagnostic features. The variability in clinical presentation underscores the importance of considering BOS in the differential diagnosis of patients presenting with unexplained sclerotic bone lesions and cutaneous papules, particularly when there is a relevant family history or other subtle clinical signs. Early recognition and accurate diagnosis are essential to prevent unnecessary investigations and to provide appropriate genetic counseling for affected individuals and their families.3

Diagnostic Methods

The diagnosis of Buschke-Ollendorff Syndrome (BOS) is primarily clinical, relying on the identification of its characteristic dermatological and osteological features—dermatofibrosis lenticularis disseminata and osteopoikilosis, respectively. However, given the often subtle and asymptomatic nature of these manifestations, particularly the osteopoikilosis, the diagnosis can be challenging. A combination of clinical examination, imaging studies, histopathological analysis, and genetic testing forms the cornerstone of an accurate diagnosis.4

CLINICAL EXAMINATION

The initial approach to diagnosing BOS begins with a thorough clinical examination. Dermatological assessment is essential to identify the characteristic papules of dermatofibrosis lenticularis disseminata. These papules, typically yellow-brown or flesh-colored, are firm, small, and often widely distributed over the trunk and extremities. They may also appear on the face and neck. While the lesions are generally asymptomatic, they are key indicators that should prompt further investigation for BOS, especially in the presence of a family history of similar lesions or known osteopoikilosis.4

During the clinical examination, a detailed medical history should be obtained, with particular attention to any family history of BOS, as the condition follows an autosomal dominant inheritance pattern. The presence of joint pain, stiffness, or any prior radiological findings of sclerotic bone lesions should also be noted, as these can provide additional diagnostic clues.4

Radiological Imaging

Radiological imaging is critical in diagnosing BOS, particularly for detecting osteopoikilosis, which is often incidentally discovered during imaging for unrelated conditions. The sclerotic bone lesions of osteopoikilosis are typically visible on standard radiographs (X-rays) as multiple, small, round, or oval areas of increased bone density. These lesions are commonly found in the epiphyses and metaphyses of long bones, as well as in the pelvis, carpal, and tarsal bones. The lesions are usually bilateral and symmetrical, a feature that helps differentiate BOS from other conditions such as osteoblastic metastases, which tend to be irregular and asymmetric.4

In addition to conventional radiography, other imaging modalities can be useful in certain cases:

- **Magnetic Resonance Imaging (MRI)**: While MRI is not routinely used for diagnosing BOS, it can be employed to further characterize the sclerotic lesions of osteopoikilosis, particularly if there is concern about differential diagnoses such as

malignancy. On MRI, the lesions typically appear as areas of low signal intensity on both T1- and T2-weighted images, reflecting their dense, sclerotic nature.5

- **Computed Tomography (CT)**: CT imaging provides more detailed anatomical information and can be used to assess the extent and distribution of osteopoikilosis. However, like MRI, CT is not generally required unless there is diagnostic uncertainty.5
- **Bone Scintigraphy**: Although bone scintigraphy is a sensitive method for detecting skeletal abnormalities, it is not particularly useful for diagnosing BOS, as the sclerotic lesions of osteopoikilosis do not usually show increased uptake on scintigraphic scans, differentiating them from active bone lesions such as metastases.5

HISTOPATHOLOGICAL ANALYSIS

Histopathological examination is often performed on skin biopsies to confirm the diagnosis of dermatofibrosis lenticularis disseminata in BOS. The biopsy typically reveals increased collagen deposition in the dermis, with a parallel arrangement of collagen fibers. The overlying epidermis may be normal or slightly atrophic, and there may be a mild perivascular inflammatory infiltrate in the dermis. The absence of significant elastin abnormalities helps differentiate these lesions from elastomas and other connective tissue nevi.5

In some cases, a bone biopsy may be performed if there is diagnostic uncertainty, particularly if there is concern about malignancy. Histologically, the sclerotic lesions of osteopoikilosis show dense, compact bone tissue with little or no marrow involvement, distinguishing them from other pathological processes.5

Genetic Testing

Genetic testing for mutations in the LEMD3 gene, located on chromosome 12q14, plays a pivotal role in confirming the diagnosis of BOS. LEMD3 encodes an inner nuclear membrane protein that interacts with the bone morphogenetic protein (BMP) and transforming growth factor-beta (TGF-β) signaling pathways. Mutations in LEMD3 disrupt the negative regulation of these pathways, leading to the abnormal bone and skin manifestations observed in BOS.5

Genetic testing is particularly valuable in cases where the clinical and radiological findings are inconclusive or when there is a need for genetic counseling, especially in familial cases. The identification of a pathogenic LEMD3 mutation confirms the diagnosis of BOS and has implications for family members, who may also be carriers of the mutation.5

Differential Diagnosis

Given the nonspecific nature of some of the clinical features of BOS, it is essential to consider and exclude other conditions that may present with similar findings. The differential diagnosis includes:5

- **Osteoblastic Metastases**: These can present with multiple sclerotic bone lesions similar to osteopoikilosis but are typically associated with a known primary malignancy, irregular and asymmetric distribution of lesions, and increased uptake on bone scintigraphy.5
- **Tuberous Sclerosis**: This genetic disorder can also present with sclerotic bone lesions and skin findings but is usually associated with other features such as cortical tubers, renal angiomyolipomas, and facial angiofibromas.5
- **Scleroderma**: Skin involvement in scleroderma can mimic the papules of BOS, but scleroderma typically involves skin thickening, Raynaud's phenomenon, and visceral organ involvement.5
- **Connective Tissue Nevi**: These are benign skin lesions that can resemble dermatofibrosis lenticularis disseminata but are usually isolated findings without associated bone lesions.5

The comprehensive evaluation of patients suspected of having BOS, incorporating clinical examination, radiological imaging, histopathological analysis, and genetic testing, ensures an accurate diagnosis. Early recognition of BOS is critical for appropriate management, avoidance of unnecessary interventions, and provision of genetic counseling.5

THERAPEUTIC APPROACHES

Buschke-Ollendorff Syndrome (BOS) is a rare genetic disorder that primarily manifests through dermatofibrosis lenticularis disseminata and osteopoikilosis. While the syndrome is generally benign and often asymptomatic, management strategies are essential to address any potential symptoms, cosmetic concerns, and to provide appropriate counseling. The therapeutic approach to BOS is primarily conservative, with interventions focused on symptom management, monitoring, and addressing patient-specific concerns. Given the genetic basis of BOS, ongoing research into targeted therapies is of interest, though as of now, treatment remains symptomatic and supportive.6

SYMPTOMATIC MANAGEMENT

Dermatological Management:

The dermatological manifestations of BOS, particularly dermatofibrosis lenticularis disseminata, are typically benign and do not require aggressive treatment. However, for patients who experience cosmetic concerns or discomfort due to the appearance of the skin lesions, several options can be considered:6

- **Topical Treatments:** Topical corticosteroids or retinoids may be employed to reduce inflammation or attempt to improve the appearance of the lesions,

though their efficacy in BOS is limited. These treatments may be helpful in managing any associated pruritus or irritation.6

- **Laser Therapy:** For patients with significant cosmetic concerns, laser therapy, particularly using vascular lasers or ablative lasers like the CO2 laser, may be considered to reduce the visibility of the papules. Laser therapy targets the collagen-rich lesions, potentially leading to a reduction in their size and visibility. However, the response to laser therapy can be variable, and the risk of scarring or pigment changes must be carefully weighed.6
- **Dermabrasion and Chemical Peels:** Although not commonly employed, dermabrasion and chemical peels may be used in some cases to improve the texture and appearance of the affected skin. These procedures exfoliate the superficial layers of the skin, which may help in diminishing the prominence of the papules. However, their effectiveness in BOS-specific lesions has not been well established.6

OSTEOLOGICAL MANAGEMENT

Osteopoikilosis, the primary osteological manifestation of BOS, is typically asymptomatic and does not require direct treatment. The sclerotic lesions do not progress to malignancy or cause functional impairment, and as such, they are often managed with a watchful waiting approach. However, for patients who may experience mild joint pain or discomfort, conservative measures can be taken:6

- **Analgesics:** Nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen can be used to manage any mild joint pain or discomfort that may be associated with osteopoikilosis. These medications are generally well-tolerated and effective in providing symptomatic relief.6
- **Physical Therapy:** In rare cases where joint stiffness or discomfort is present, physical therapy may be recommended to maintain joint mobility and function. Stretching exercises, strengthening routines, and modalities such as heat therapy can help alleviate symptoms.6
- **Monitoring and Reassurance:** Given that osteopoikilosis does not lead to serious complications, reassurance is an important aspect of management. Patients should be informed about the benign nature of the condition and the lack of need for aggressive intervention. Regular follow-up with radiographic monitoring may be considered, though this is not typically necessary unless new symptoms develop.6

Genetic Counseling and Family Planning

As BOS is an autosomal dominant genetic disorder, genetic counseling plays a critical role in the management of affected individuals and their families. Counseling should focus on:

- **Risk Assessment:** Genetic counseling should provide a comprehensive assessment of the risk of transmission to offspring, given the 50% chance of passing the mutated LEMD3 gene to the next generation. This information is essential for family planning and decision-making.6
- **Prenatal and Preimplantation Genetic Diagnosis (PGD):** For families with a known history of BOS, prenatal testing or preimplantation genetic diagnosis (PGD) may be offered. These options allow for early identification of the LEMD3 mutation in the fetus or embryo, enabling informed decisions about pregnancy continuation or the selection of unaffected embryos during in vitro fertilization (IVF).6
- **Psychosocial Support:** Given the potential psychosocial impact of living with a genetic disorder, counseling should also address the emotional and psychological aspects of BOS. This includes discussing any concerns about the cosmetic appearance of skin lesions, the implications of genetic transmission, and the management of any associated symptoms.6

EMERGING THERAPIES AND FUTURE DIRECTIONS

The management of BOS is currently limited to symptomatic and supportive care, but advances in genetic research and molecular medicine hold promise for more targeted therapies in the future:6

- **Gene Therapy:** As our understanding of the LEMD3 gene and its role in BOS continues to evolve, the possibility of gene therapy to correct the underlying genetic defect becomes a potential avenue for treatment. While still in the experimental stages, gene therapy could one day offer a curative approach for BOS by directly addressing the molecular basis of the syndrome.6
- **Targeted Molecular Therapies:** Research into the TGF-β signaling pathway, which is dysregulated in BOS due to LEMD3 mutations, could lead to the development of targeted therapies that modulate this pathway. By restoring normal signaling, these therapies could potentially prevent or reverse the development of the characteristic bone and skin lesions associated with BOS.6
- **Clinical Trials:** Participation in clinical trials investigating new therapies for genetic skin and bone disorders may be an option for patients with BOS, particularly in the context of emerging treatments that target the specific molecular mechanisms involved in the syndrome.6

Interdisciplinary Management

Given the multisystem involvement in BOS, an interdisciplinary approach to care is recommended. Collaboration between dermatologists, orthopedists, geneticists, and primary care physicians ensures comprehensive management that addresses all aspects of the syndrome:

- **Dermatology:** Dermatologists play a key role in the diagnosis and management of dermatofibrosis lenticularis disseminata and in providing cosmetic and symptomatic care.6
- **Orthopedics:** Orthopedic consultation may be necessary for patients with osteopoikilosis, particularly if there are concerns about joint function or pain, although surgical intervention is rarely, if ever, required.6
- **Genetics:** Geneticists are essential for providing accurate diagnosis, risk assessment, and counseling, as well as for exploring potential participation in research or clinical trials.6
- **Primary Care:** Ongoing monitoring and coordination of care by a primary care physician ensure that all aspects of the patient's health are managed, and that referrals to specialists are made as needed.6

While the therapeutic approaches to Buschke-Ollendorff Syndrome are largely conservative and symptomatic, ongoing research into the genetic and molecular basis of the syndrome offers hope for more targeted and potentially curative treatments in the future. Comprehensive management that includes genetic counseling, symptomatic care, and interdisciplinary collaboration is essential to address the needs of patients with BOS and to provide the best possible outcomes.6

CONCLUSION

Buschke-Ollendorff Syndrome (BOS) is a rare, inherited disorder characterized by the presence of dermatofibrosis lenticularis disseminata and osteopoikilosis. Despite its benign nature, the syndrome presents a unique challenge in clinical practice due to its variable expressivity, subtle presentation, and potential for misdiagnosis. The cornerstone of management lies in a thorough clinical examination, supported by radiological imaging and, when necessary, histopathological analysis and genetic testing. The identification of mutations in the LEMD3 gene has not only facilitated accurate diagnosis but also underscored the genetic underpinnings of the disorder, providing a basis for genetic counseling and future therapeutic developments.

The dermatological manifestations, though primarily of cosmetic concern, may require intervention in cases where they significantly impact the patient's quality of life. Current treatment options are limited to symptomatic care, with laser therapy and topical treatments offering some benefit for those with distressing skin lesions. On the other hand, the osteological component of BOS, represented by osteopoikilosis, is generally asymptomatic and does not necessitate active treatment. However, the recognition of these characteristic bone lesions is crucial to prevent unnecessary investigations and to differentiate BOS from other conditions with similar radiographic findings, such as osteoblastic metastases or other sclerosing bone dysplasias.

The management of BOS extends beyond symptomatic treatment to include genetic counseling, which plays a pivotal role in guiding affected individuals and their families. The autosomal dominant inheritance pattern necessitates a clear understanding of the genetic risks, particularly for family planning and the consideration of prenatal testing or preimplantation genetic diagnosis (PGD). Counseling also addresses the psychosocial aspects of the syndrome, providing support for patients as they navigate the implications of living with a genetic disorder.

Looking ahead, the future of BOS management lies in advances in molecular medicine and genetic therapy. As our understanding of the LEMD3 gene and its role in the pathogenesis of BOS deepens, there is potential for the development of targeted therapies that could modify the disease process at a molecular level. Gene therapy, while still in its infancy, represents a promising avenue for research, with the potential to offer a curative approach for patients with BOS. Additionally, the exploration of the TGF-β signaling pathway, which is implicated in the development of BOS, could lead to novel therapeutic strategies that prevent or mitigate the clinical manifestations of the syndrome.

In conclusion, while Buschke-Ollendorff Syndrome remains a largely benign and manageable condition, it is a disorder that exemplifies the importance of genetic insight in the diagnosis and management of rare diseases. The ongoing research into its molecular mechanisms holds the promise of more targeted and effective therapies in the future, underscoring the need for continued investigation into the genetic and biochemical pathways that underlie this intriguing syndrome. By combining current clinical strategies with emerging scientific advances, healthcare providers can offer comprehensive care to patients with BOS, ensuring not only accurate diagnosis and symptom management but also the hope of future therapeutic innovations.

REFERENCES

I. Pope V, Dupuis L, Kannu P, Mendoza-Londono R, Sajic D, So J, Yoon G, Lara-Corrales I. Buschke-Ollendorff syndrome:a novel case series and systematic review. *Br J Dermatol.* 2016;174(4):723–9.

II. Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, Savarirayan R, Van Hul W, Vanhoenacker F, Huylebroeck D, De Paepe A,

Naeyaert JM, Vandesompele J, Speleman F, Verschueren K, Coucke PJ, Mortier GR. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. *Nat Genet.* 2004;36(11):1213–8.

III. Buschke A, Ollendorff H. Ein Fall von Dermatofibrosis lenticularis disseminata und Osteopathia condensans disseminata. *Dermatol Wochenschr.* 1928;86:257.

IV. McCuaig CC, Vera C, Kokta V, Marcoux D, Hatami A, Thuraisingam T, Marton D, Fortier-Riberdy G, Powell J. Connective tissue nevi in children: institutional experience and review. *J Am Acad Dermatol.* 2012;67(5):890–7.

V. Wordsworth P, Chan M. Melorheostosis and Osteopoikilosis:A Review of Clinical Features and Pathogenesis. *Calcif Tissue Int.* 2019;104(5):530–543.

VI. Mumm S, Wenkert D, Zhang X, McAlister WH, Mier RJ, Whyte MP. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. *J Bone Miner Res.* 2007;22(2):243–50.